Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prenetics Group ( (PRE) ) has shared an announcement.
Prenetics Global Limited, a consumer health sciences company and parent of the IM8 premium health and longevity brand, reported that 2025 was a transformational year marked by record growth and a strategic refocus on IM8. The company divested non-core units including ACT Genomics, its Europa distribution business and its stake in Insighta, resulting in about $171 million of adjusted liquidity and a simplified operating structure as of mid-February 2026.
For the year ended December 31, 2025, Prenetics’ revenue surged about 480% year over year to $92.4 million, with fourth-quarter revenue reaching $36.6 million on strong IM8 momentum. IM8 generated $60.1 million of 2025 revenue, hit $10 million in monthly sales in December and achieved an annualized recurring revenue run-rate of roughly $120 million just 12 months after launch.
The IM8 business showed robust unit economics in 2025, including a blended average order value of about $110, a roughly 3.4‑month payback period and a projected 24‑month lifetime value-to-customer acquisition cost ratio of about 3x. By the end of the fourth quarter, IM8’s quarterly revenue rose 59% from the prior quarter, while customer orders and servings delivered grew more than 30%, underscoring strong product-market fit and recurring demand.
Geographically, IM8’s $60.1 million in 2025 revenue was diversified, with the United States accounting for $23.8 million, followed by Canada, the United Kingdom, Australia and Singapore, and more than 60% of revenue coming from outside the U.S. The company reported that IM8 shipped to over 30 countries during the year, establishing a global footprint that supports its expansion plans in 2026.
In late 2025 and early 2026, Prenetics shifted new IM8 customers from monthly to quarterly subscription plans to boost upfront cash flow and improve logistics efficiency. This move drove a step-change in blended average order value from about $110 for full-year 2025 to $133 in the fourth quarter and roughly $233 for new customers in January and February 2026, albeit with a deliberate increase in customer acquisition costs to secure higher-value, longer-duration subscribers.
To support brand positioning, Prenetics deepened IM8’s ties to elite sports by adding world No. 1 tennis player Aryna Sabalenka as a global ambassador and shareholder in June 2025 and Formula 1 driver Ollie Bearman in February 2026. These partnerships, alongside co-founder David Beckham, are intended to reinforce IM8’s image as a premium performance and recovery brand and to broaden its reach among health-focused consumers and athletes worldwide.
The most recent analyst rating on (PRE) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
Overall score is constrained by weak financial performance (ongoing losses and negative operating/free cash flow), partially offset by strong technical trend and momentum. Valuation remains unattractive due to negative earnings and no dividend support.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited is a consumer health sciences company listed on Nasdaq, best known as the parent of IM8, a premium health and longevity supplement brand co-founded with David Beckham. The company targets health-conscious consumers globally with subscription-based nutrition products, distributing to more than 30 countries with a strong presence in the U.S., Canada, the U.K., Australia and Singapore.
Average Trading Volume: 197,526
Technical Sentiment Signal: Hold
Current Market Cap: $369.7M
For an in-depth examination of PRE stock, go to TipRanks’ Overview page.